Bright Minds Biosciences (DRUG) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Neurogene (NGNE) over the past year, losing 12.0% versus a loss of 16.3%. Over five years, DRUG leads with a +45.5% price change compared with -81.7% for NGNE. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $528.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | NGNE |
|---|---|---|
| Share price | $54.05 | $26.40 |
| Market cap | $533.15M | $528.30M |
| 1-day change | +3.94% | -0.38% |
| YTD return | -30.74% | +28.16% |
| 1-year return | -11.99% | -16.35% |
| 5-year return | +45.49% | -81.72% |
| EPS (TTM) | $-2.05 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $43.66 |
| 52-week low | $47.23 | $15.93 |
| Distance from 52-week high | -56.32% | -39.53% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +181.17% | +195.00% |
| Average volume | 155.37K | 249.87K |
| Shares outstanding | 9.86M | 20.01M |
| Employees | 26 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
DRUG vs NGNE FAQ
Which is bigger, Bright Minds Biosciences or Neurogene?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $528.30M for Neurogene (NGNE).
Which stock has performed better over the past year, DRUG or NGNE?
DRUG returned -11.99% over the past 12 months, compared with -16.35% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.